X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Rizafilm (rizatriptan) binds with high affinity to human cloned 5-HT1B/1D receptors. It has received FDA approval for the Treatment of acute migraine. It is approved in EU under the name rizaport.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizafilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Rizafilm (rizatriptan) binds with high affinity to human cloned 5-HT1B/1D receptors. It has received FDA approval for the Treatment of acute migraine. It is approved in EU under the name rizaport.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizafilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gensco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Rizafilm (rizatriptan) binds with high affinity to human cloned 5-HT1B/1D receptors. It has received FDA approval for the Treatment of acute migraine. It is approved in EU under the name rizaport.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizafilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
The Company intends to use the proceeds of the Offering to finance the Company’s Rizaport (rizatriptan) and Buprenorphine programs. Rizaport is a novel, competitive and differentiated oral thin film formulation of rizatriptan for the acute treatment of migraine.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizaport
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantone Research
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 21, 2023
Details:
RIZAPORT® is the first rizatriptan oral disintegrating film for the treatment of migraines to achieve E.U. marketing approval. Rizatriptan is a selective 5-HT1B/1D receptor agonist indicated for the treatment of migraines.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizaport
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: AXS-07
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: AXS-07
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan. The NDA is supported by results from two Phase 3 trials of MOMENTUM and INTERCEPT.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: AXS-07
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
AXS-07, the Company’s novel, oral, multi-mechanistic investigational medicine for the acute treatment of migraine, rapidly relieved and substantially reduced relapse of migraine pain, as compared to the potent active comparator rizatriptan, in the MOMENTUM Phase 3 trial.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: AXS-07
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
The results of the Phase 3 MOMENTUM trial were one of the 12 selected abstracts. The Phase 3 Momentum Trial evaluated efficacy and safety of AXS-07 for the acute treatment of migraine.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: AXS-07
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizaport
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exeltis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 27, 2020
Details:
AXS-07 met the co-primary endpoints of freedom from migraine pain and freedom from most bothersome symptoms as compared to placebo.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
IntelGenx recently received from the U.S. FDA Complete Response Letter regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®.
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
The Phase 3, randomized, double-blind, placebo-controlled trial is evaluating the early treatment of migraine with AXS-07. AXS-07.
Lead Product(s): Meloxicam,Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
